Role of Antibiotic Therapy or Immunoglobulin On iNfections in hAematoLogy Platform Trial (RATIONAL-PT)

This is an adaptive platform study to find out how safe and effective different strategies are in comparison to each other, for preventing infection in patients with blood cancers. It is a comparison between Immunoglobulin and antibiotics use.

Trial Details

NCT ID
NCT07202052
Phase
PHASE2 / PHASE3
Sponsor
Monash University
Status
RECRUITING
Cancer Type
Multiple Myeloma
Interventions
  • Intravenous immunoglobulin
  • Trimethoprim / Sulfamethoxazole
  • Amoxicillin clavulanic acid
  • Intravenous immunoglobulin (IVIG)
Locations (sample)
  • Adelaide, South Australia, Australia|-34.92866,138.59863
  • Melbourne, Victoria, Australia|-37.814,144.96332
  • Melbourne, Victoria, Australia|-37.814,144.96332

Key Eligibility Criteria

  • Aged greater than or equal to 18 years of age
  • Diagnosis of haematological malignancy, including (CLL) chronic lymphocytic leukemia, (MM) multiple myeloma or (NHL) non-Hodgkin's lymphoma.
  • Eligible to receive or currently receiving Ig (IV or subcutaneous - SCIg) replacement for history of recurrent or severe infection(s) and IgG less …
  • Life expectancy \> 12 months

For full eligibility, visit ClinicalTrials.gov.

Check If You May Be Eligible

Trialify translates complex eligibility criteria into plain yes-or-no questions to help you understand if this trial might be right for you.

Find Multiple Myeloma Trials on Trialify →